Protalix BioTherapeutics, Inc.

Higher Single PRX-115 Doses Kept Plasma Uric Acid Levels Below Therapeutic Target for Longer Durations

Protalix BioTherapeutics Presents Data Supporting Potential for Less Frequent Dosing in Phase 2 RELEASE Study for Uncontrolled Gout The Company…